PT - JOURNAL ARTICLE AU - Yoo, Seunghoon AU - You, Dae Hyuk AU - Lee, Jeongyoon AU - Hong, H. Christian AU - Lee, Sung Jin TI - A Nonrandomized Phase 2 Trial of EG-Mirotin, a Novel, First-in-class, Subcutaneously Delivered Peptide Drug for Non-Proliferative Diabetic Retinopathy AID - 10.1101/2021.12.30.21267814 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.30.21267814 4099 - http://medrxiv.org/content/early/2022/01/05/2021.12.30.21267814.short 4100 - http://medrxiv.org/content/early/2022/01/05/2021.12.30.21267814.full AB - Background EG-Mirotin, which includes an active ingredient; EGT022, targeting Non-Proliferative Diabetic Retinopathy (NPDR), the early stage of retinopathy. EG-Mirotin is a drug that is used before capillary damage progresses to an irreversible stage. Safety and efficacy of EG-Mirotin were investigated in subjects with Type 1 or 2 diabetes and NPDR with the degree from moderate to severe.Methods Subjects (n=10, 20 eyes) satisfying the selection criteria through the screening test were administered EG-Mirotin once a day (3 mg in 1.5 ml of sterile saline) for 5 days, 5 times in total, and were evaluated of the Ischemic index changes and safety. End-of-study (EOS) is performed approximately 8 weeks ± 1 (57 days ± 7) from the first dose.Results A total of 4 Treatment Emergent Adverse Events (TEAE) were observed in 2 subjects out of 10 (20.00%) who received the investigational drug. Among them, no subjects were reported experiencing a TEAE related to the investigational drug. All injections were well tolerated (3 mg in 1.5 ml of sterile saline) with no dose-limiting adverse events, deaths, serious adverse events. The overall average percent change in ischemic index at each evaluation point compared to baseline was statistically significant (Greenhouse-Geisser F=9.456, p=0.004 for the main effect of time), and a larger change was observed when the baseline ischemic index value was high (Greenhouse-Geisser F=10.946, p=0.002 for the time*group interaction).Conclusions EG-Mirotin was well tolerated and found to reverse the ischemia and leakage of capillaries in the retina caused by diabetes.Competing Interest StatementDae Hyuk You, Jeongyoon Lee, and Sung Jin Lee are independently contracted consultants of EyeGene Inc. and H. Christian Hong is an employee of EyeGene Inc. Clinical TrialClinical Research Information System (CRIS): KCT0005124 The above KCT0005124 has been listed in International Clinical Trials Registry Platform by World Health Organization: https://trialsearch.who.int/Trial2.aspx?TrialID=KCT0005124Funding StatementThis study was funded by EyeGene Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Soonchunhyang University Hospital gave ethical approval for this work: SCHUH2020-03-004I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors